Pharmacological Agents for Chronic Spinal Cord Injury (SCI)

The Role of Pharmacological Agents in Restoring Neuronal Excitability After Chronic Spinal Cord Injury (SCI)

The purpose of this study is to investigate the short-term effects of 3 approved FDA drugs (cyproheptadine (CPH), carbidopa-levodopa (CD-LD), and atomoxetine (ATX)) on motor responses when delivered in combination with hand training exercises in people with chronic spinal cord injury. The goal is to learn how to better strengthen connections between the brain and spinal cord after spinal cord injury, and if this connection is improved by one(or more) of the drugs. Multiple aspects of nerve transmission and muscle response will be measured via noninvasive brain and spinal cord stimulation, along with motor performance (dexterity and strength).

Study Overview

• Status: Recruiting
• Conditions: Spinal Cord Injuries
• Intervention / Treatment: Drug: CPH + hand training; Drug: CD-LD + hand training; Drug: ATX + hand training; Drug: Placebo + hand training

Detailed Description

Research will take place at the James J. Peters VA Medical Center (JJPVAMC), Bronx, NY. There are seven visits in total, including an initial evaluation and clinical assessment session. Each visit will last roughly 5 hours or less. We plan to enroll 28 participants with spinal cord injury over a two-year period.

The study is designed as a double-blind, placebo-controlled, single-dose, randomized crossover investigation involving four study drug visits (CPH, CD-LD, ATX, or placebo).

The same participants will partake in all four interventions in randomized order with at least 1-week washout representative of greater than 5x drug half-life; to avoid accumulative effects. To reduce potential learning effects from motor training and task-related outcome measurements, participants will partake in two motor training practice sessions prior to commencing the experiments for task familiarity.

This study will consist of electromyography (surface recordings of muscle activity), peripheral nerve stimulation, transcranial magnetic brain stimulation (TMS), and transcutaneous electrical spinal cord stimulation (TSCS), targeting the hand/arm muscles.

Though it is unlikely given the single-dose nature, participants may experience side effects following drug administration. Prior to consenting, all volunteers will undergo a comprehensive pre-screening evaluation including blood tests to ensure there are no contraindications.

Please note, there is no expectation of long-term benefit from this study.

• Study Type: Interventional
• Enrollment (Anticipated): 28
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Lynda M Murray, PhD; Phone Number: 5426 718-584-9000; Email: lynda.murray@va.gov
• Study Contact Backup: Name: Noam Y Harel, MD PhD; Phone Number: 1742 718-584-9000; Email: noam.harel@va.gov

Study Locations

• United States
  • New York
    • Bronx, New York, United States, 10468
      • Recruiting
      • James J. Peters Veterans Affairs Medical Center
      • Contact: Lynda M Murray, PhD; Phone Number: 5426 718-584-9000; Email: lynda.murray@va.gov

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male or female between 18 and 65 years of age; clinically stable chronic (> 12 months) SCI at or above C8 spinal segment;
• Motor-incomplete with a score of 2 or more (out of 5) on manual muscle testing (MMT) of finger extension, finger flexion, or finger abduction in left or right hand(s); or able to perform thumb-index finger pinch of the left or right hand;
• Detectable stimulation-evoked muscle responses of the left or right first dorsal interosseous (FDI) and/or abductor pollicis brevis (APB); Detectable FDI/APB surface electromyography (EMG) muscle activity during thumb-index finger pinch;
• Must have stable: medication [≥ 30 days prior]; rehabilitation regimen [≥ 15 days prior];
• Must be able to: abstain from alcohol, smoking and caffeine consumption on the day prior/of each experiment; abstain from recreational drugs for the entirety of the study; commit to study requirements (i.e., 7 visits); provide informed consent.

Exclusion Criteria:

• History of moderate or severe head trauma (loss of consciousness for greater than one hour or evidence of brain contusion or hemorrhage or depressed skull fracture on prior imaging);
• History of other serious central or peripheral neurological injury;
• History of implanted brain/spine/nerve stimulators, aneurysm clips, ferromagnetic metallic implants in the head (except inside mouth); cochlear implants; cardiac pacemaker/defibrillator; intracardiac lines; currently increased intracranial pressure; or other contraindications to brain stimulation or task performance;
• Ventilator dependence or patent tracheostomy site;
• Unstable syrinx, or multiple spinal cord lesions;
• Unclear diagnosis; History of stroke, brain tumor, brain abscess, or multiple sclerosis;
• Personal history of seizures; extensive family history of seizures; use of medications that lower seizure threshold (e.g., amphetamines, dalfampridine, and bupropion);
• Use of the study medications; Use of medications known to have significant adverse interactions with the study medication as described in the manufacturers' prescribing information [14 days prior]; previous allergic reaction or hypersensitivity to study drug(s);
• Presence of a medical condition that represents a risk for study drug(s) administration; evidence of liver disease or clinical jaundice; neutropenia; glaucoma; gastrointestinal ulcer(s); active malignancy; undiagnosed skin lesions; autoimmune disorders; chronic infectious diseases (e.g. HIV, hepatitis B or C); pregnancy or nursing mothers (a pregnancy urine test may be warranted); neurologic disorders (including a history of serious head trauma or seizures), and uncontrolled cardiovascular, metabolic, pulmonary or renal disease; premorbid, ongoing major depression or psychosis, altered cognitive status; bipolar disorder; suicidal ideation or past suicide attempts;
• History of severe hearing problems, loss or tinnitus;
• Presence of urinary infection, fever, pressure ulcer; or open skin lesions (shoulders or arms);
• Recent history (< 6 months) of recurrent autonomic dysreflexia, defined as a syndrome of sudden rise in systolic pressure greater than 20 mm Hg or diastolic pressure greater than 10 mm Hg, without rise in HR, accompanied by symptoms such as headache, facial flushing, sweating, nasal congestion, and blurry vision (closely monitored during all testing procedures);
• Heavy alcohol consumption (greater than equivalent of 5 oz of liquor) within previous 48 hours;
• Recent history (>1 year) of chemical substance dependency or significant psychosocial disturbance;
• Study participation of an investigational drug or device [60 days prior];
• Unsuitable for study participation as determined by the study physician.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CPH + hand training; A single dose of Cyproheptadine (CPH) (8 mg) will be administered. Supplied as 2 over-encapsulated pills of 4 mg each.	Drug: CPH + hand training; Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
Experimental: CD-LD + hand training; A single dose of IR Carbidopa-levodopa (CD-LD) (50/200 mg) will be administered. Supplied as 2 over-encapsulated pills (25 mg carbidopa / 100 mg levodopa each).	Drug: CD-LD + hand training; Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
Experimental: ATX + hand training; A single dose of Atomoxetine (ATX) (40 mg) will be administered. Supplied as 1 over-encapsulated pill of 40 mg plus 1 placebo capsule.	Drug: ATX + hand training; Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
Placebo Comparator: Placebo + hand training; A single dose of Placebo will be administered. Supplied as 2 gelatin capsules, identical in number, size, shape and color, filled with microcrystalline cellulose.	Drug: Placebo + hand training; Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessing task performance (dexterity)	Unilateral manual dexterity will be assessed using the 9-Hole Peg Test (Aim 1a).	Assess change from baseline to 10 minutes after completion of drug+task training.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessing task performance (dexterity)	Unilateral manual dexterity will be assessed using the Box and Block Test (Aim 1a).	Assess change from baseline to 10 minutes after completion of drug+task training.
Assessing volitional grip strength	Maximal grip force will be measured (Aim 1b). The attempt with the highest value will be used for analysis.	Assess change from baseline to 10 minutes after completion of drug+task training.
Assessing volitional pinch strength	Maximal pinch force will be measured (Aim 1b). The attempt with the highest value will be used for analysis.	Assess change from baseline to 10 minutes after completion of drug+task training.
Assessing corticospinal plasticity	Corticospinal plasticity will be measured via single-pulse TMS recruitment curves (Aim 2a).	Assess change from baseline to 10 minutes after completion of drug+task training.
Assessing cortical plasticity	Short intracortical inhibition (SICI) and intracortical facilitation (ICF) will be evoked with paired-pulse TMS at various interstimulus intervals according to the methods previously employed (Murray & Knikou, 2017).	Assess change from baseline to 10 minutes after completion of drug+task training.
Assessing spinal plasticity	Spinal plasticity will be measured via single-pulse TSCS recruitment curves (Aim 2b).	Assess change from baseline to 10 minutes after completion of drug+task training.
Tracking cardiovascular responses (heart rate)	Observed measures of heart rate (HR) (Aim 3a) will be monitored throughout.	Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline.
Tracking cardiovascular responses (blood oxygen saturation)	Observed measures of blood oxygen saturation (SpO2) (Aim 3a) will be monitored throughout.	Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline.
Tracking cardiovascular responses (blood pressure)	Observed measures of blood pressure (BP) (Aim 3a) will be monitored throughout.	Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline.
Tracking symptoms	Participant-reported safety questionnaire (Aim 3b) will be monitored for any symptoms felt throughout the study.	Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline.
Tracking side effects (drug administration)	Adverse event (AE) questionnaire (Aim 3b) related to any participant-reported experience following drug administration.	Assess change from end of day 1 testing to 24 hours after study completion.
Tracking side effects (study testing stimulation)	Adverse event (AE) questionnaire (Aim 3b) related to any participant-reported experience following brain and/or spinal stimulation received during the experiment.	Assess change from end of day 1 testing to 24 hours after study completion.

Collaborators and Investigators

• Sponsor: Bronx VA Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): January 20, 2023
• Primary Completion (Anticipated): July 30, 2024
• Study Completion (Anticipated): July 30, 2024

Study Registration Dates

• First Submitted: December 27, 2022
• First Submitted That Met QC Criteria: January 23, 2023
• First Posted (Actual): February 1, 2023

Study Record Updates

• Last Update Posted (Actual): April 24, 2023
• Last Update Submitted That Met QC Criteria: April 21, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: Transcranial magnetic stimulation; Transcutaneous spinal cord stimulation; Hand exercise; Pharmacological agents
• Additional Relevant MeSH Terms: Central Nervous System Diseases; Nervous System Diseases; Trauma, Nervous System; Spinal Cord Diseases; Wounds and Injuries; Spinal Cord Injuries
• Other Study ID Numbers: JJPVAMC IRB 1685818

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Deidentified, individual-level data will be deposited to appropriate public repositories, such as Open Data Commons for Spinal Cord Injury (https://scicrunch.org/odc-sci), Figshare, or others.

This will allow more powerful meta-analysis of disparate smaller studies, a need which is even more urgent in neurorehabilitation than in other fields that are more amenable to large drug studies.

• IPD Sharing Time Frame: Within 6 months of manuscript preparation.

IPD Sharing Access Criteria

Authorization, Informed Consent, and an appropriate written agreement limiting use of the data to the conditions described in the authorization and consent.

A Data Use Agreement (DUA) will indicate adherence to any applicable Informed Consent provisions, and prohibits the recipient from identifying or re-identifying any individual whose data are included in the dataset.

• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No